Skoči na glavni sadržaj

Izvorni znanstveni članak

Second Generation Antipsychotics and Risk of Diabetes Type II – Comparison between Olanzapine and Risperidone

Pavo Filaković
Oliver Koić
Davor Laufer
Ljiljana Radanović-Grgurić
Dunja Degmečić
Ivan Požgain

Puni tekst: engleski pdf 66 Kb

str. 1105-1109

preuzimanja: 669



Differences in the glucose metabolism were examined and analysed in this study between patients treated with olanzapine
and risperidone in comparison with healthy volunteers. The aim of the study was to determine differences of the
impaired glucose metabolism in the study groups as well as to point out to the possible mechanisms which bring to these
differences. To the group of 15 schizophrenic patients treated with olanzapine, and group of 15 schizophrenic patients
treated with risperidone and to 14 healthy volunteers oral glucose tolerancy test is applied in order to determine the level
of the impaired glucose tolerance. In the group of the patients treated with olanzapine glucose tolerance was impaired in
33% of the patients, while in the group of the patients treated with risperidone in 20%. Impaired glucose tolerance mostly
manifested as hyperinsulinemia. Authors discussed about possible mechanisms responsible for the impaired glucose tolerance
in the patients treated with new antipsychotics. Authors conclude that insulin resistance is the main mechanism
for development of the diabetes type II in the schizophrenic patients treated with antipsychotics. Insulin resistance is the
result of the multiple effects of the antipsychotics, among which most common are: increased body mass and direct involvement
of the antipsychotics in the glucose metabolism.

Ključne riječi

schizophrenia, second generation antipsychotics, glucose metabolism

Hrčak ID:



Posjeta: 1.081 *